HB
Highly rated in
15
conditions

Dr. Hossein Borghaei

Fox Chase Cancer Center
Philadelphia, PA
Highly rated in
15
conditions
Specialties:Oncology | Radiology | Hematology
Experience:27 Years
Clinical Trials:Currently Recruiting for 7 Trials
Accepts:New PatientsMedicare
Highly rated in
15
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Hossein Borghaei's experience treating your condition:
About Dr. Hossein Borghaei

Hossein Borghaei is an Oncologist and a Radiologist in Philadelphia, PA. Borghaei has been practicing medicine for over 27 years and is highly rated in 15 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Small Cell Lung Cancer (SCLC), Salpingo-Oophorectomy, and Gamma Knife Radiosurgery. He is licensed to treat patients in Pennsylvania. Borghaei is currently accepting new patients.

His clinical research consists of co-authoring 101 peer reviewed articles and participating in 25 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Hossein Borghaei it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Hossein Borghaei accepts the following insurance:

  •  Ambetter
Call to see if your plan is accepted.
Locations
333 Cottman Ave, Philadelphia, PA
Background & Education
Graduate Institution
Philadelphia College Of Osteopathic Medicine, 1996
Residency
Graduate Hospital
Specialties
Oncology
Radiology
Hematology
Licenses
Specialist in PA
Fellowships
Fox Chase Cancer Center
Hospital Affiliations
Suburban Community Hospital
St Mary Medical Center
Temple University Hospital - Jeanes Campus
Fox Chase Cancer Center
Languages Spoken
English
Spanish
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials
Neoadjuvant Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 2
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 05, 2022
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Enrollment Status: Recruiting
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: Sotorasib
Study Phase: Phase 2
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Enrollment Status: Recruiting
Publish Date: October 19, 2022
Intervention Type: Drug, Dietary Supplement, Biological
Study Drugs: DexamethasoneDocetaxelGemcitabineNogapendekin AlfaPembrolizumabPemetrexedRamucirumab
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma
Enrollment Status: Recruiting
Publish Date: April 07, 2022
Intervention Type: Drug
Study Drugs: NivolumabRamucirumab
Study Phase: Phase 2
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Recruiting
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Recruiting
Publish Date: December 14, 2022
Intervention Type: Drug, Biological
Study Drugs: CarboplatinPembrolizumabPemetrexed
Study Phase: Phase 3
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Enrollment Status: Active, not recruiting
Publish Date: November 14, 2022
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)
Enrollment Status: Terminated
Publish Date: August 15, 2022
Intervention Type: Drug
Study Drugs: PDR001CisplatinGemcitabinePemetrexedCarboplatinPaclitaxelCanakinumab
Study Phase: Phase 1
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Biological, Drug, Other
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: DocetaxelPalbociclib
Study Phase: Phase 2/Phase 3
A Single-center Study to Evaluate the Feasibility of a Novel NA-NOSE for Monitoring Response to and Detecting Recurrence After Surgery or Radiation in Early Stage Lung Cancer
Enrollment Status: Active, not recruiting
Publish Date: October 13, 2022
Intervention Type: Other, Procedure
Study Phase: Not Applicable
CancerCodeTM Informed, Molecularly Targeted Therapies in Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: September 04, 2019
Intervention Type: Procedure, Other, Drug
Study Phase: Not Applicable
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: May 18, 2022
Intervention Type: Biological, Other
Study Drugs: DurvalumabTremelimumab
Study Phase: Phase 2
Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
Enrollment Status: Completed
Publish Date: January 12, 2021
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Enrollment Status: Active, not recruiting
Publish Date: May 05, 2022
Intervention Type: Drug
Study Drugs: AvelumabTalazoparibTalazoparib Tosylate
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Active, not recruiting
Publish Date: October 15, 2021
Intervention Type: Drug, Biological
Study Drugs: DocetaxelGemcitabineGemcitabine HydrochloridePembrolizumabPemetrexedPemetrexed DisodiumRamucirumab
Study Phase: Phase 2
Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors
Enrollment Status: Active, not recruiting
Publish Date: September 23, 2022
Intervention Type: Biological, Drug
Study Drugs: VEGFR/PDGFR Dual Kinase Inhibitor X-82Nivolumab
Study Phase: Phase 1/Phase 2
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active, not recruiting
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 17, 2018
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active, not recruiting
Publish Date: May 25, 2022
Intervention Type: Other, Biological
Study Drugs: IpilimumabNivolumab
Study Phase: Phase 3
Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer
Enrollment Status: Completed
Publish Date: July 12, 2022
Intervention Type: Drug
Study Drugs: BevacizumabErlotinib
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.
Enrollment Status: Active, not recruiting
Publish Date: December 12, 2019
Intervention Type: Drug
Study Drugs: PembrolizumabCarboplatinNab-paclitaxelPemetrexed
Study Phase: Phase 2
View 18 Less Clinical Trials -
101 Total Publications
Advances in immune checkpoint inhibition for patients with lung cancer.
Journal: Clinical advances in hematology & oncology : H&O
Published: November 04, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
DG
Dr. Daniel M. Geynisman
Oncology | Transplant Surgery
Highly rated in
13
conditions
Oncology
Transplant Surgery

Temple University Health System

Fox Chase Cancer Center

333 Cottman Ave, 
Philadelphia, PA 
 0.4 mi

Daniel Geynisman is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Geynisman has been practicing medicine for over 17 years and is highly rated in 13 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Chromophobe Renal Cell Carcinoma, Urothelial Cancer, and Orchiectomy. He is licensed to treat patients in Pennsylvania. Geynisman is currently accepting new patients.

SB
Stefan K. Barta
Dr. Stefan K. Barta
Hematology Oncology | Transplant Surgery | Hematology
Highly rated in
37
conditions
Hematology Oncology
Transplant Surgery
Hematology

Penn Medicine

Perelman Center For Advanced Medicine

3400 Civic Center Blvd, 
Philadelphia, PA 
 10.1 mi

Stefan Barta is a Hematologist Oncology specialist and a Transplant Surgeon in Philadelphia, Pennsylvania. Barta has been practicing medicine for over 24 years and is highly rated in 37 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Pennsylvania. Barta is currently accepting new patients.

ES
Dr. Edward A. Stadtmauer
Hematology | Oncology | Hematology Oncology
Highly rated in
34
conditions
Hematology
Oncology
Hematology Oncology

Penn Medicine

Perelman Center For Advanced Medicine

3400 Civic Center Blvd, 
Philadelphia, PA 
 10.1 mi

Edward Stadtmauer is a Hematologist and an Oncologist in Philadelphia, Pennsylvania. Stadtmauer has been practicing medicine for over 40 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Pennsylvania. Stadtmauer is currently accepting new patients.